Achieve Life Sciences Teams With Omnicon on Nicotine Dependence Treatment

Dow Jones

06/27

By Natalie Weger

Achieve Life Sciences is partnering with marketing company Omnicom to lead Achieve's commercial launch of a potential new treatment for nicotine dependence in the U.S.

The pharmaceutical company on Thursday said the collaboration would create a data-driven launch of its treatment.

Achieve submitted its new drug application for cytisinicline, a treatment of nicotine dependence, for approval from the Food and Drug Administration on Wednesday.

The Vancouver, British Columbia, company on Thursday also made a proposed underwritten public offering of its common stock. It intends to grant underwriters a 30-day option to purchase up to an additional 15% of common stock shares or accompanying common warrants. Achieve didn't detail the size or terms of the offering.

The company plans to use the proceeds to fund its cytisinicline advancement through FDA marketing and for other corporate purposes.

Write to Natalie Weger at natalie.weger@wsj.com

(END) Dow Jones Newswires

June 26, 2025 16:56 ET (20:56 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2546875118"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2546875118\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2546875118?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-27 04:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2546875118","market":"other","top_or_hot":-1,"title":"Achieve Life Sciences Teams With Omnicon on Nicotine Dependence Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Natalie Weger \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ACHV\">Achieve Life</a> Sciences is partnering with marketing company Omnicom to lead Achieve's commercial launch of a potential new treatment for nicotine dependence in the U.S. \n</p>\n<p>\n  The pharmaceutical company on Thursday said the collaboration would create a data-driven launch of its treatment. \n</p>\n<p>\n  Achieve submitted its new drug application for cytisinicline, a treatment of nicotine dependence, for approval from the Food and Drug Administration on Wednesday. \n</p>\n<p>\n  The Vancouver, British Columbia, company on Thursday also made a proposed underwritten public offering of its common stock. It intends to grant underwriters a 30-day option to purchase up to an additional 15% of common stock shares or accompanying common warrants. Achieve didn't detail the size or terms of the offering. \n</p>\n<p>\n  The company plans to use the proceeds to fund its cytisinicline advancement through FDA marketing and for other corporate purposes. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Natalie Weger at natalie.weger@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 26, 2025 16:56 ET (20:56 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Achieve Life Sciences Teams With Omnicon on Nicotine Dependence Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAchieve Life Sciences Teams With Omnicon on Nicotine Dependence Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-06-27 04:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Natalie Weger \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ACHV\">Achieve Life</a> Sciences is partnering with marketing company Omnicom to lead Achieve's commercial launch of a potential new treatment for nicotine dependence in the U.S. \n</p>\n<p>\n  The pharmaceutical company on Thursday said the collaboration would create a data-driven launch of its treatment. \n</p>\n<p>\n  Achieve submitted its new drug application for cytisinicline, a treatment of nicotine dependence, for approval from the Food and Drug Administration on Wednesday. \n</p>\n<p>\n  The Vancouver, British Columbia, company on Thursday also made a proposed underwritten public offering of its common stock. It intends to grant underwriters a 30-day option to purchase up to an additional 15% of common stock shares or accompanying common warrants. Achieve didn't detail the size or terms of the offering. \n</p>\n<p>\n  The company plans to use the proceeds to fund its cytisinicline advancement through FDA marketing and for other corporate purposes. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Natalie Weger at natalie.weger@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 26, 2025 16:56 ET (20:56 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2546875118","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546875118","pubTimestamp":1750971360,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Achieve Life Sciences is partnering with marketing company Omnicom to lead Achieve's commercial launch of a potential new treatment for nicotine dependence in the U.S.The pharmaceutical company on Thursday said the collaboration would create a data-driven launch of its treatment.Achieve submitted its new drug application for cytisinicline, a treatment of nicotine dependence, for approval from the Food and Drug Administration on Wednesday.The Vancouver, British Columbia, company on Thursday also made a proposed underwritten public offering of its common stock. It intends to grant underwriters a 30-day option to purchase up to an additional 15% of common stock shares or accompanying common warrants. Achieve didn't detail the size or terms of the offering.The company plans to use the proceeds to fund its cytisinicline advancement through FDA marketing and for other corporate purposes.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4009":"广告","LU0742537680.HKD":"FIDELITY GLOBAL DIVIDEND \"A \" (HKD) INC","LU1599440770.SGD":"FIDELITY GLOBAL DIVIDEND \"A\" (SGDHDG) INC","ACHV":"Achieve Life Sciences, Inc.","LU0772969993.USD":"FIDELITY GLOBAL DIVIDEND \"A\" (USD) ACC","BK4139":"生物科技","LU0731783048.USD":"FIDELITY GLOBAL DIVIDEND \"A\" (USD) INC MONTHLY (G)","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU1509826696.USD":"FIDELITY GLOBAL DIVIDEND \"A\" (USD) INC B","LU1481011671.HKD":"FIDELITY GLOBAL DIVIDEND \"A\" (HKDHDG) INC","LU0731783394.SGD":"Fidelity Global Dividend A-MINCOME(G)-SGD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","OMC":"宏盟集团","LU1481011911.USD":"FIDELITY GLOBAL DIVIDEND \"A\" (USDHDG) INC"},"translate_title":"与Omnicon合作实现生命科学团队的尼古丁依赖治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACHV":0.9,"OMC":0.9},"content_text":"By Natalie Weger \n\n\n \n\n\nAchieve Life Sciences is partnering with marketing company Omnicom to lead Achieve's commercial launch of a potential new treatment for nicotine dependence in the U.S. \n\n\n  The pharmaceutical company on Thursday said the collaboration would create a data-driven launch of its treatment. \n\n\n  Achieve submitted its new drug application for cytisinicline, a treatment of nicotine dependence, for approval from the Food and Drug Administration on Wednesday. \n\n\n  The Vancouver, British Columbia, company on Thursday also made a proposed underwritten public offering of its common stock. It intends to grant underwriters a 30-day option to purchase up to an additional 15% of common stock shares or accompanying common warrants. Achieve didn't detail the size or terms of the offering. \n\n\n  The company plans to use the proceeds to fund its cytisinicline advancement through FDA marketing and for other corporate purposes. \n\n\n \n\n\n  Write to Natalie Weger at natalie.weger@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 26, 2025 16:56 ET (20:56 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}